Clinical trials: RSV
Bronchiolitis
Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants
Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV).
- Trial name
- BRONCHOBIOTE (NCT06161285)
- Testing
- Sampling
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Congenital Heart Disease in Children, RSV
Adherence to Palivizumab Prophylaxis
The goal of this clinical trial is to analyze implications of two alternative nudge-interventions to increase adherence to palivizumab prophylaxis in children with congenital heart disease.
- Trial name
- NCT05778240
- Testing
- Phone call, Text message, Control
- Where
- Turkey (Türkiye)
- Volunteers
- 229 people
- Sponsor
- Kosuyolu Heart Hospital
Bronchiolitis, Clinical Phenotype
Short-Term Enteral Nutrition for Infants With Bronchiolitis in Pediatric Emergency Departments
Bronchiolitis is a common viral infection of the small airways that affects infants, particularly during respiratory syncytial virus epidemics.
- Conditions
- Bronchiolitis, Clinical Phenotype, Nutritionnal Impairment, Short-Term Enteral Nutrition
- Trial name
- STENP-PER (NCT07901400)
- Testing
- Usual inpatient bronchiolitis care, STENP-PER care pathway
- Where
- 8 sites in France
- Volunteers
- 448 people
- Sponsor
- Hospices Civils de Lyon
Chronic Lung Disease
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
The purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab.
- Trial name
- NCT00233064
- Testing
- Lyophilized Palivizumab, Liquid Palivizumab
- Where
- 54 sites in United States
- Volunteers
- 417 people
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (sisunatovir). Sisunatovir is developed as potential treatment of Respiratory Syncytial Virus (RSV) infections.
- Trial name
- REVIRAL 1 (NCT04225897)
- Testing
- RV521
- Where
- 60 sites in Argentina, Canada and 13 more
- Volunteers
- 51 people
- Sponsor
- Pfizer
Respiratory Viral Infections, Respiratory Syncytial Virus Infections
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
The overall objective of the MEDI-534 clinical development program is to evaluate the safety, efficacy and tolerability of MEDI-534 for the prevention of serious RSV and PIV3 disease in young infants.
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Trial name
- CP149 (NCT00493285)
- Testing
- MEDI-534
- Where
- 30 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Respiratory Syncytial Virus
A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections
The purpose of the study is to assess viral kinetics and clinical symptoms kinetics in pediatric patients hospitalized with Respiratory Syncytial Virus (RSV) confirmed lower respiratory tract infection (LRTI).
- Trial name
- NCT02133092
- Testing
- No intervention
- Where
- 4 sites in Belgium
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Tract Infections, Respiratory Syncytial Virus Infections
Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus
Infection with human respiratory syncytial (RS) virus is the most common cause of hospital stay due to pediatric lower respiratory tract infection.
- Trial name
- IMAR (NCT03757429)
- Testing
- RS-virus infection
- Where
- Sweden
- Volunteers
- 31 people
- Sponsor
- Uppsala University
RSV Infection, Bronchiolitis
Evaluation of Lung Ultrasonography Findings in Newborns With Respiratory Syncytial Virus Bronchiolitis
Respiratory Syncytial Virus (RSV) is a seasonal, highly contagious pathogen belonging to the Pneumoviridae (genus orthopneumovirus), a family of negative-strand RNA viruses.
- Trial name
- NCT06204367
- Testing
- Lung Ultrasonografisi
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Kırıkkale University
Bronchiolitis; Respiratory Syncytial Virus
COVID-19 Impact on RSV Emergency Presentations
Bronchiolitis is a very common winter disease that normally affects children less than one year of age. It is a common reason for parents and carers to bring their child to an Emergency Department (ED) and the frequent need for…
- Trial name
- BronchSTART (NCT04959734)
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospitals, Leicester
Bronchiolitis, Viral
Steroid Use in Non-RSV Bronchiolitis
The proposed study is a pilot randomized control trial to determine the efficacy of dexamethasone use in hospitalized children who are less than 2 years of age with non-respiratory syncytial virus (RSV) bronchiolitis admitted to…
- Trial name
- NCT04221087
- Testing
- Dexamethasone Oral
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Allison Williams
RSV
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile.
- Trial name
- NCT06511687
- Testing
- Nirsevimab
- Where
- Chile
- Volunteers
- 160,000 people
- Sponsor
- Instituto Sistemas Complejos de Ingeniería
Respiratory Syncytial Virus Infections
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
- Trial name
- RSVTx (NCT04633187)
- Testing
- EDP-938
- Where
- 64 sites in United States, Argentina and 17 more
- Volunteers
- 9 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Fever, Adverse Event Following Immunisation
Safety of RSV Preventive Monoclonal Antibody
This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other routine childhood vaccines given simultaneously…
- Trial name
- NCT07158814
- Testing
- Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
- Where
- 6 sites in United States
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Duke University
Respiratory Syncytial Virus Infections
RSV Observational Study 2
Respiratory Syncytial Virus (RSV) is a virus that causes chest infections. It is the single most important cause of severe respiratory illness in infants and young children, and severe RSV infection early in life is associated…
- Trial name
- NCT01922648
- Testing
- Blood sample
- Where
- United Kingdom
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Congenital Heart Disease
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
- Trial name
- NCT00538785
- Testing
- Motavizumab, Palivizumab
- Where
- 152 sites in United States, Austria and 15 more
- Volunteers
- 1,236 people
- Sponsor
- MedImmune LLC
Motavizumab Administration for a Second Season for RSV Prophylaxis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children
The primary objective of this study was to determine the effect on immune reactivity to motavizumab (MEDI-524) of monthly intramuscular (IM) doses of motavizumab (MEDI-524) administered for a second season in children.
- Trial name
- NCT00113490
- Testing
- motavizumab (MEDI-524), palivizumab 15 mg/kg
- Where
- 6 sites in Brazil, Chile
- Volunteers
- 136 people
- Sponsor
- MedImmune LLC
Viral Bronchiolitis
Evaluation of Chest Physiotherapy for Acute Bronchiolitis in Toddlers (BRONKINOU)
The purpose of this study is to determine whether chest physiotherapy with forced expiratory technique reduces delay of healing in acute bronchiolitis of children between 15 days and 24 months of age.
- Trial name
- BRONKINOU (NCT00125450)
- Testing
- Chest Physiotherapy with Forced Expiratory Technique, Nasopharyngeal Aspiration
- Where
- 7 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Bronchiolitis
Acute Bronchiolitis and Severity Markers: Interest in Protein CC16
Acute bronchiolitis is a common viral infection in infants mainly due to RSV and rhinovirus. Biomarkers can be useful for predicting its severity. The serum CC16 is a marker of epithelial aggression.
- Trial name
- CC16 (NCT02984046)
- Testing
- Protein CC16
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Respiratory Syncytial Virus Hospitalizations
An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants
Purpose of this study is to evaluate clinical, humanistic and health economic burden of Respiratory Syncytial Virus (RSV) in infants born 29 to 35 Weeks Gestational Age (wGA) hospitalized for RSV at up to 12 months of age.
- Trial name
- SENTINEL1 (NCT02273882)
- Where
- 44 sites in United States
- Volunteers
- 497 people
- Sponsor
- AstraZeneca